ILLUMINATE-A, a phase 3 study of lumasiran, an investigational RNAi therapeutic, in children and adults with primary hyperoxaluria type 1 (PH1)

被引：0

作者：

Garrelfs, Sander ^{[1
]}

Frishberg, Yaacov ^{[2
]}

Hulton, Sally ^{[3
]}

Koren, Michael ^{[4
]}

O'Riordan, William ^{[5
]}

Cochat, Pierre ^{[6
,7
,8
]}

Deschenes, Georges ^{[9
]}

Shasha-Lavsky, Hadas ^{[10
]}

Saland, Jeffrey ^{[11
]}

van't Hoff, William ^{[12
]}

Fuster, Daniel G. ^{[13
]}

Magen, Daniella ^{[14
]}

Moochhala, Shabbir ^{[15
]}

Schalk, Gesa ^{[16
]}

Simkova, Eva ^{[17
]}

Groothoff, Jaap ^{[1
]}

Sas, David ^{[18
]}

Meliambro, Kristin ^{[11
]}

Lu, Jiandong ^{[19
]}

Garg, Pushkal ^{[19
]}

Gansner, John ^{[19
]}

McGregor, Tracy ^{[19
]}

Lieske, John ^{[18
]}

机构：

[1] Amsterdam UMC, Dept Pediat Nephrol, Amsterdam, Netherlands

[2] Shaare Zedek Med Ctr, Div Pediat Nephrol, Jerusalem, Israel

[3] Birmingham Childrens Hosp, Dept Nephrol, Birmingham, W Midlands, England

[4] Jacksonville Ctr Clin Res, Jacksonville, FL USA

[5] EStudySite, San Diego, CA USA

[6] Hosp Civils Lyon, Lyon, France

[7] Univ Lyon, Ctr Rare Renal Dis, Lyon, France

[8] INSERM, Pediat Clin Invest Ctr, Lyon, France

[9] Hosp Robert Debre, Dept Pediat Nephrol, Paris, France

[10] Galilee Med Ctr, Nahariyya, Israel

[11] Icahn Sch Med, New York, NY USA

[12] Great Ormond St Hosp Sick Children, Dept Pediat Nephrol, London, England

[13] Univ Bern, Div Nephrol & Hypertens, Inselspital, Univ Hosp Bern, Bern, Switzerland

[14] Rambam Hlth Care Campus, Dept Pediat Nephrol, Haifa, Israel

[15] Royal Free Hosp, London, England

[16] Univ Bonn, Bonn, Germany

[17] Al Jalila Childrens Hosp, Dubai, U Arab Emirates

[18] Mayo Clin, Rochester, MN USA

[19] Alnylam Pharmaceut, Cambridge, MA USA

来源：

SWISS MEDICAL WEEKLY | 2020年

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OC 15

引用

页码：8S / 8S

页数：1

共 50 条

[21] LUMASIRAN LOWERED URINARY OXALATE IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 IRRESPECTIVE OF PYRIDOXINE USE, HYDRATION STATUS, AND GENOTYPE IN THE PHASE 3 CLINICAL TRIAL ILLUMINATE-A
Saland, Jeffrey
Ngo, Taylor
Gansner, John
McGregor, Tracy
Lieske, John
AMERICAN JOURNAL OF KIDNEY DISEASES, 2021, 77 (04) : 644 - 644
[22] DIGESTIVE MANIFESTATIONS OF PRIMARY HYPEROXALURIA TYPE1(PH1) IN CHILDREN
Gazzeh, Souhir
Nouir, Selsabil
Mabrouk, Sameh
Tfifha, Meniar
Ajmi, Houda
Majdoub, Fadwa
Jaleleddine, Chemli
Zouari, Noura
Saoussen, Abroug
PEDIATRIC NEPHROLOGY, 2021, 36 (10) : 3468 - 3469
[23] THE CHALLENGE DIAGNOSTIC AND THERAPEUTIC OF PRIMARY HYPEROXALURIA TYPE 1 (PH1): A CASE REPORT
Malgieri, Gabriele
Francesca, Caprio
Rossella, Colantuono
Bruno, Minale
Zulli, Enrico
Darcangelo, Rosamunda
Pecoraro, Carmine
PEDIATRIC NEPHROLOGY, 2021, 36 (10) : 3454 - 3455
[24] Identification of new mutations in primary hyperoxaluria type 1 (PH1)
von Schnakenburg, C
Rumsby, G
JOURNAL OF NEPHROLOGY, 1998, 11 : 15 - 17
[25] LUMASIRAN DEMONSTRATED COMPARABLE OXALATE REDUCTION AND SAFETY IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1
Shasha-Lavsky, Hadas
Garrelfs, Sander
Sas, David
Lieske, John
Ngo, Taylor
Makarova, Nune
Gansner, John
McGregor, Tracy
Frishberg, Yaacov
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
[26] Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial
Hayes, Wesley
Sas, David J.
Magen, Daniella
Shasha-Lavsky, Hadas
Michael, Mini
Sellier-Leclerc, Anne-Laure
Hogan, Julien
Ngo, Taylor
Sweetser, Marianne T.
Gansner, John M.
McGregor, Tracy L.
Frishberg, Yaacov
PEDIATRIC NEPHROLOGY, 2023, 38 (04) : 1075 - 1086
[27] Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial
Wesley Hayes
David J. Sas
Daniella Magen
Hadas Shasha-Lavsky
Mini Michael
Anne-Laure Sellier-Leclerc
Julien Hogan
Taylor Ngo
Marianne T. Sweetser
John M. Gansner
Tracy L. McGregor
Yaacov Frishberg
Pediatric Nephrology, 2023, 38 : 1075 - 1086
[28] Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial
Frishberg, Yaacov
Hayes, Wesley
Shasha-Lavsky, Hadas
Sas, David J.
Michael, Mini
Sellier-Leclerc, Anne-Laure
Hogan, Julien
Willey, Richard
Gansner, John M.
Magen, Daniella
FRONTIERS IN PEDIATRICS, 2024, 12
[29] GENETIC-ANALYSIS OF PATIENTS WITH PRIMARY HYPEROXALURIA TYPE-1 (PH1)
FRISHBERG, Y
REINER, O
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 621 - 621
[30] Lumasiran for Patients With Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 12-Month Analysis of the Phase 3 ILLUMINATE-C Trial
Frishberg, Yaacov
Michael, Mini
Groothoff, Jaap
Shasha-Lavsky, Hadas
Lieske, John C.
Simkova, Eva
Sellier-Leclerc, Anne-Laure A.
Devresse, Arnaud
Egziabher, Fitsum Guebre
Bakkaloglu, Sevcan A.
Mourani, Chebl
Saqan, Rola
Singer, Richard F.
Willey, Richard G.
Gansner, John M.
Magen, Daniella
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 416 - 416

← 1 2 3 4 5 →